Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer (NCT00430183)
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and leuprolide, may stop the adrenal glands from making androgens. Giving docetaxel and leuprolide or goserelin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether giving docetaxel and leuprolide or goserelin before surgery is more effective than surgery alone in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Providence Cancer Center — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (226 Sites)
Showing the first 25 of 226 sites.
- Providence Cancer Center — Anchorage, Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital — Fairbanks, Alaska
- Alta Bates Summit Comprehensive Cancer Center — Berkeley, California
- Peninsula Medical Center — Burlingame, California
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California
- Sutter Health - Western Division Cancer Research Group — Novato, California
- University of California Davis Cancer Center — Sacramento, California
- Naval Medical Center - San Diego — San Diego, California
- California Pacific Medical Center - Pacific Campus — San Francisco, California
- Sutter Pacific Medical Foundation — Santa Rosa, California
- Tahoe Forest Cancer Center — Truckee, California
- Sutter Solano Medical Center — Vallejo, California
- University of Colorado Cancer Center at UC Health Sciences Center — Aurora, Colorado
- Denver Health Medical Center — Denver, Colorado
- Veterans Affairs Medical Center - Denver — Denver, Colorado
- Shaw Regional Cancer Center — Edwards, Colorado
- Valley View Hospital Cancer Center — Glenwood Springs, Colorado
- Montrose Memorial Hospital Cancer Center — Montrose, Colorado
- Helen and Harry Gray Cancer Center at Hartford Hospital — Hartford, Connecticut
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center — Hartford, Connecticut
- Yale Cancer Center — New Haven, Connecticut
- Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut
- Veterans Affairs Medical Center - West Haven — West Haven, Connecticut
- Tunnell Cancer Center at Beebe Medical Center — Lewes, Delaware
- CCOP - Christiana Care Health Services — Newark, Delaware
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.